Sonidegib Side Effects
Medically reviewed by Drugs.com. Last updated on Oct 18, 2023.
Applies to sonidegib: oral capsule.
Warning
Oral route (Capsule)
Use of sonidegib during pregnancy can cause embryofetal death or severe birth defects. Verify pregnancy status prior to initiating treatment and advise females of reproductive potential to use adequate contraception during treatment and for at least 20 months after discontinuation. Male patients with a female partner of reproductive potential must be advised to use adequate contraception during treatment for at least 8 months after discontinuation.
Serious side effects of Sonidegib
Along with its needed effects, sonidegib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking sonidegib:
More common
- Difficulty with moving
- joint pain
- muscle aching or cramping
- muscle pains or stiffness
- muscle spasms
- swollen joints
Rare
- Dark-colored urine
- fever
- muscle stiffness
- unusual tiredness or weakness
Other side effects of Sonidegib
Some side effects of sonidegib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- Abdominal or stomach pain
- change in taste
- decreased appetite
- decreased weight
- diarrhea
- hair loss or thinning of the hair
- headache
- itching skin
- loss of taste
- nausea
- vomiting
For Healthcare Professionals
Applies to sonidegib: oral capsule.
Musculoskeletal
Very common (10% or more): Increased serum creatinine (92%), increased serum creatinine kinase (61%), muscle spasms (54%), musculoskeletal pain (32%), myalgia (19%)
Uncommon (0.1% to 1%): Rhabdomyolysis[Ref]
75% of patients with increased serum creatinine had levels that remained within normal range.[Ref]
Dermatologic
Very common (10% or more): Alopecia (53%), pruritus (10%)
Common (1% to 10%): Rash, abnormal hair growth[Ref]
Metabolic
Very common (10% or more): Hyperglycemia (51%), dysgeusia (46%), decreased weight (30%), decreased appetite (23%)
Common (1% to 10%): Dehydration[Ref]
Nervous system
Very common (10% or more): Dysgeusia (46%), headache (15%)[Ref]
Gastrointestinal
Very common (10% or more): Increased lipase (43%), nausea (39%), diarrhea (32%), abdominal pain (18%), increased amylase (16%), vomiting (11%)
Common (1% to 10%): Dyspepsia, constipation, GI reflux[Ref]
Other
Very common (10% or more): Fatigue (41%), pain (14%)[Ref]
Hematologic
Very common (10% or more): Anemia (32%), lymphopenia (28%)[Ref]
Hepatic
Very common (10% or more): Increased ALT (19%), increased AST (19%)[Ref]
Endocrine
Frequency not reported: Amenorrhea[Ref]
Frequently asked questions
More about sonidegib
- Check interactions
- Compare alternatives
- Reviews (1)
- Dosage information
- During pregnancy
- Drug class: hedgehog pathway inhibitors
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
References
1. Cerner Multum, Inc. Australian Product Information.
2. Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals. 2015.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.
